COPD
Conditions
Interventions
We conducted a randomized, crossover study comparing the efficacy of LABA between transdermal tulobuterol patch (TP, 2 mg once a day) and inhaled salmeterol (50microgram, twice a day) in elderly COPD
Sponsors
Tokyo Metropolitan Geriatric Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients had clinical features consistent with the presence of moderate-to-severe COPD including spirometric criteria of post-bronchodilator FEV1/FVC ratio of less than 0.7 and FEV1 between 30% and 80% of the predicted values for height and age, and kept stable conditions during the past month.
Exclusion criteria
Exclusion criteria: Exclusion criteria included age younger than 65, dementia and any previously usage of inhaled medications such as beta 2-agonists, anti-cholinergics or corticosteroids, patched beta 2--agonist, or systemic corticosteroids. Patients with dermatological disorders, severe heart diseases, uncontrolled hypertension or other diseases for whom patch preparations or treatments with beta 2-agonists was considered inappropriate were also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcomes were relationship between change in sprirometric values and 6-minute walk distance (6MWD) and SNP of beta 2-adrenergic receptors in each medication (tulobuterol patch and inhaled salmeterol therapy). The secondary outcomes were quality of life (QOL) measured by St.George's Respiratory Questionnaire. | — |
Countries
Japan
Contacts
Public ContactHideki Takahashi
Tokyo Metropolitan Geriatric Hospital Division of Respiratory Medicine
Outcome results
None listed